Related Experiment Video

Updated: Jun 23, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

TP-110, a new proteasome inhibitor, down-regulates IAPs in human multiple myeloma cells

Masatomi Iijima1, Isao Momose, Daishiro Ikeda

  • 1Numazu Bio-Medical Research Institute, Microbial Chemistry Research Center, Shizuoka 410-0301, Japan. iijimam@bikaken.or.jp

Anticancer Research
|May 6, 2009
PubMed

Insights

TP-110, a proteasome inhibitor, triggers apoptosis in multiple myeloma cells by reducing inhibitor of apoptosis proteins (IAPs). This mechanism enhances cancer cell death and offers potential therapeutic strategies for leukemia.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cellular Biology

Background:

  • Proteasome inhibitors are investigated for cancer therapy.
  • TP-110 demonstrates potent growth inhibition in tumor cells.
  • Understanding TP-110's mechanism of action is crucial.

Purpose of the Study:

  • To investigate the mechanism of TP-110-induced apoptosis.
  • To examine the role of apoptosis regulatory proteins in TP-110's effects.
  • To analyze TP-110's impact on inhibitor of apoptosis proteins (IAPs).

Main Methods:

  • In vitro treatment of human multiple myeloma cell line (RPMI8226) with TP-110.
  • Analysis of apoptosis markers including Bid cleavage and cytochrome c release.
  • Assessment of Bcl-2 family proteins and inhibitor of apoptosis proteins (IAPs) expression.
  • Comparison with another proteasome inhibitor, MG-132.

Main Results:

  • TP-110 induced apoptosis in RPMI8226 cells.
  • Bid cleavage and cytochrome c release were enhanced by TP-110.
  • TP-110 reduced levels of cIAP-1 and XIAP, key inhibitors of apoptosis.
  • Proteasome inhibitors, including TP-110 and MG-132, decrease IAP levels.
  • TP-110-induced IAP reduction sensitized cells to Fas-mediated apoptosis.

Conclusions:

  • Proteasome inhibitors reduce inhibitor of apoptosis proteins (IAPs).
  • TP-110 induces apoptosis in multiple myeloma cells, partly via IAP modulation.
  • The alteration of apoptosis regulatory proteins by proteasome inhibitors contributes to tumor cell death.

More Related Videos

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

Assessment of Selective mRNA Translation in Mammalian Cells by Polysome Profiling10:00

Assessment of Selective mRNA Translation in Mammalian Cells by Polysome Profiling

Published on: October 28, 2014

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...